

REMARKS***Sequence Compliance***

At page 2 of the pending Office Action, the Examiner has requested compliance with the requirements of 37 C.F.R. §§1.821-1.825.

In response to this request, the specification has been amended to insert sequence identifiers where appropriate (including sequence identifiers for those amino acid sequences noted by the Examiner). Moreover, enclosed herewith is a diskette which contains a Sequence Listing in computer readable form as required by 37 C.F.R. § 1.821(e). Also enclosed is a paper copy of the Sequence Listing and a statement that the contents of the paper copy and the computer readable copy of the Sequence Listing are the same as required by 37 C.F.R. § 1.821(f). A copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures is also enclosed herewith.

Claim Amendments

Claims 1-98 were pending. Claims 25-27, 31, 35 and 39 have been canceled without prejudice. Claims 12, 14, 16, 18, 19, 22-24, 28-30, 32-34, 36-38, 40-46, 48-50, and 58 have been amended. New claims 99-104 have been added. Accordingly, claims 1-24, 28-30, 32-34, 36-38, and 40-102 are currently pending.

Claims 12, 14, 16, 18 and 19 have been amended without prejudice to delete reference to overlapping sequence homologies.

Claims 22-24 have been amended to specify both the heavy and light chain variable region CDR3 sequences, CDR2 sequences, and CDR1 sequences, respectively, of antibody AB7. Support for these amendments can be found throughout the specification as originally filed.

Claims 28-30 have been amended to specify both the heavy and light chain variable region CDR3 sequences, CDR2 sequences, and CDR1 sequences, respectively, of antibody AB11. Support for these amendments can be found throughout the specification as originally filed.

Claims 32-34 have been amended to specify both the heavy and light chain variable region CDR3 sequences, CDR2 sequences, and CDR1 sequences, respectively, of antibody

AB12. Support for these amendments can be found throughout the specification as originally filed.

Claims 36-38 have been amended to specify both the heavy and light chain variable region CDR3 sequences, CDR2 sequences, and CDR1 sequences, respectively, of antibody AB1. Support for these amendments can be found throughout the specification as originally filed.

Claims 40-46 and 48-50 have been amended to insert the appropriate sequence identifiers. Support for these amendments can be found throughout the specification as originally filed.

Claim 58 has been amended to provide appropriate claim dependency.

New claims 99-102 are drawn to human anti-CD25 antibodies comprising human heavy and light chain variable regions encoded by or comprising specific heavy and light chain CDR1, 2 and 3 sequences. Support for new claims 99-102 can be found throughout the specification as originally filed.

New claims 103 and 104 correspond to original claims 24 and 25.

The foregoing claim amendments were made in response to the restriction requirement and pursuant to the telephonic interview discussed below. Applicants reserve the right to pursue the claims as originally filed in this or a separate application(s). No new matter has been added.

Restriction Requirement

Pursuant to 37 CFR §1.133(b), Applicants acknowledge with appreciation the telephonic interview, held on June 14, 2006, during which the subject restriction requirement was discussed. Specifically, the Examiner has required restriction of the claims among thirty (30) different groups. However, during the interview, Applicants requested the Examiner to reconsider the restriction to the extent that claims drawn to particular human antibodies having specific heavy and light chain CDR3 sequences, as well as antibodies having the corresponding full length variable region sequences, would be searched together in the present application in the order elected below. In other words, Applicants requested that, upon finding the first elected CDR3 and corresponding variable region sequences free of the prior art, the Examiner would continue to search the CDR3 and corresponding variable region sequences of the remaining three antibodies exemplified in the specification.

Accordingly, Applicants elect Group 12 (claims 32-35) comprising amino acid sequences from the heavy and light chain variable regions of AB12, with traverse. Applicants respectfully reiterate herein their request for reconsideration of the restriction requirement as summarized above and discussed during the telephonic interview. Pursuant to their request, Applicants elect for searching purposes the heavy and light chain variable region CDR3 sequences encompassed by antibody AB12, SEQ ID NOs:37 and 40, respectively, as well as the corresponding full length heavy and light chain variable regions, SEQ ID NOs:14 and 16, respectively. Applicants note that a search of the elected CDR3 sequences necessarily covers the corresponding elected full length variable region sequences.

If the elected sequences are found free of the prior art, Applicants respectfully elect for continued searching the remaining antibodies exemplified in the specification as follows:

- (a) the heavy and light chain variable region CDR3 sequences encompassed by antibody AB1, SEQ ID NOs:19 and 22, respectively, as well as the corresponding full length heavy and light chain variable regions, SEQ ID NOs:2 and 4, respectively;
- (b) the heavy and light chain variable region CDR3 sequences encompassed by antibody AB7, SEQ ID NOs:25 and 28, respectively, as well as the corresponding full length heavy and light chain variable regions, SEQ ID NOs:6 and 8, respectively; and
- (c) the heavy and light chain variable region CDR3 sequences encompassed by antibody AB11, SEQ ID NOs:31 and 34, respectively, as well as the corresponding full length heavy and light chain variable regions, SEQ ID NOs:10 and 12, respectively.

For the Examiner's convenience, Applicants provide the following chart which summarizes the elected sequences and correlates the pending claims to these sequences.

Order of Election	CDR3 Pairing (SEQ ID NO)	Var. Reg. Pairing (SEQ ID NO)	Claims Reading on Elected Invention
AB12	37 and 40	14 and 16	1-6, 8, 13, 14, 19, 32-34, 51, 53-56, 67, 99
AB1	19 and 22	2 and 4	1-6, 9, 15, 16, 19, 36-38, 40-50, 52, 53-56, 67, 100

AB7	25 and 28	6 and 8	1-7, 12, 19-24, 51, 53-56, 67, 101, 103, 104
AB11	31 and 34	10 and 12	1-6, 10, 17-19, 28-30, 52-56, 67, 102


Further, it is Applicants understanding that the withdrawn method claims that depend from or otherwise include all the limitations of any of the product claims which are deemed allowable will be rejoined in accordance with the provisions of MPEP §821.04.

CONCLUSION

If a telephone conversation with Applicants' attorney would help expedite the prosecution of the above-identified application, the Examiner is urged to call the undersigned at (617) 227-7400.

Dated: June 29, 2006

Respectfully submitted,

By 
Jeanne M. DiGiorgio
Registration No.: 41,710
LAHIVE & COCKFIELD, LLP
28 State Street
Boston, Massachusetts 02109
(617) 227-7400
(617) 742-4214 (Fax)
Attorney/Agent For Applicant